Supplementary material to article by J. Zweegers et al. "Effectiveness of Biologic and Conventional Systemic Therapies in Adults with Chronic Plaque Psoriasis in Daily Practice: A Systematic Review"

## Table SI. Inclusion and exclusion criteria

Inclusion criteria

Chronic plaque psoriasis

Prospective or retrospective

Thirty participants or more

Daily practice, database, registries, "real-world", "real-life", observational, cohort

Patients aged ≥ 18 years

English, Dutch or German language

Article reports on one of the following effectiveness outcomes: PASI, PhGA on a scale of 0-5, 0-6 or 0-7 or BSA

Reporting on the effectiveness of following treatments: adalimumab, etanercept, infliximab, ustekinumab, acitretin, fumarates, cyclosporine, or methotrexate

Reporting data analysed with the as-treated approach (per protocol analysis)

Exclusion criteria

Case reports

RCTs or clinical trials

Safety studies

In vitro studies and other laboratory studies

Pharmacokinetic studies

Cost-effectiveness studies

Open-label studies with a stringent protocol not reflecting daily practice

Studies not reporting the time point at which effectiveness was measured

Studies not reporting the dosage of treatment

Studies not reporting data separately per treatment

Studies reporting solely on non-systemic treatments such as phototherapy and topical therapies

Studies reporting solely on alefacept or efalizumab since these agents are no longer available for psoriasis treatment

Articles reporting on a combination of plaque psoriasis with other subtypes of psoriasis when the effectiveness data solely on chronic plaque psoriasis could not be extracted from the article

Studies describing only outcomes on psoriatic arthritis

Studies on specific psoriasis patient populations (e.g. psoriasis patients with HIV or hepatitis)

Studies in which conventional systemic agents were combined with other conventional systemic therapies

In patient cohorts treated with biologics, combination with conventional systemic was not excluded but described when appropriate

RCT: randomized controlled trial; PASI: Psoriasis Area and Severity Index; PhGA: Physician's Global Assessment; BSA: body surface area.